Jennifer Koh

  • Partner
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
  • T +1.858.523.5400


Jennifer Koh, a partner in Latham & Watkins’ Intellectual Property Litigation Practice, represents clients in patent matters pertaining to pharmaceuticals, biotechnology, and life sciences. In particular, she represents brand pharmaceutical companies in trials and Federal Circuit appeals arising under the Hatch-Waxman Act.

Ms. Koh handles all aspects of pre-trial and trial preparation, including presenting and cross-examining fact and expert witnesses at trial. She also litigates inter partes review proceedings before the US Patent and Trademark Office (USPTO). She works closely with clients to develop intellectual property strategies and coordinate with FDA regulatory strategies.

Prior to law school, Ms. Koh conducted research in vascular and hepatic tissue engineering at Duke University and the University of California, San Diego.

Ms. Koh is the local office chair of Latham’s Women Enriching Business Committee. Ms. Koh is also a board member of the San Diego Volunteer Lawyer Program, and is regularly involved in pro bono matters supporting children, immigrants, and veterans. Ms. Koh has also guest lectured at the Rady School of Management since 2015.


A sample of the cases Ms. Koh has handled includes representing:

  • Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC in a patent suit involving a generic version of Par’s Adrenalin® brand epinephrine injection. The court ruled in Par’s favor, finding that the generic infringed all asserted patent claims, and that Par’s patents were valid.
  • Endo Pharmaceuticals Inc. in patent suits involving generic versions of Endo’s brand Nascobal® cyanocobalamin nasal spray. The parties entered consent judgments that Endo’s six patents-in-suit were valid, enforceable, and infringed.
  • Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC in a declaratory judgment patent suit relating to Par’s Orange Book-listed patents for Vasostrict® vasopressin injection. The court granted Par’s motion to dismiss and entered final judgment for Par.

Thought Leadership

  • Tech, Pharma Divided Over Section 101 Challenges Post-Alice -  July 03, 2017
  • Federal Circuit Returns the On-Sale Bar to Status Quo for AIA Patents -  June 07, 2017
  • Pharmaceutical and Software Industries at Odds on Potential Section 101 Reform -  May 15, 2017
Bar Qualification
  • California
  • US Patent and Trademark Office
  • JD, University of San Diego School of Law, 2005
  • MS in Bioengineering, University of California, San Diego, 2003
  • BSE Biomedical Engineering, Duke University, 2001
  • Healthcare & Life Sciences
  • Intellectual Property Litigation
  • Litigation & Trial Practice